Payment overview · 2025
General Payments
$281.76
15 reported records · 7 companies
Healthcare provider profile · identity verified
Emily Ager, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CHATTANOOGA, TN · NPI 1235593880
Verified facts
What the public records show
CMS Open Payments records show Emily Ager, M.D. received $281.76 in general payments during 2025 across 15 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $78.50 | 27.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.90 | 27.3% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $36.02 | 12.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.60 | 12.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.95 | 7.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.83 | 7.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.96 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $281.76 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76.90 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $49.23 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.40 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $36.02 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.60 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $29.27 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.83 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 102 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 46 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 85 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
102 | 32 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
85 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 403 | 140 |
| Atorvastatin Calcium | Atorvastatin Calcium | 403 | 131 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 332 | 99 |
| Losartan Potassium | Losartan Potassium | 281 | 96 |
| Lisinopril | Lisinopril | 280 | 89 |
| Gabapentin | Gabapentin | 251 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 198 | 61 |
| Omeprazole | Omeprazole | 180 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 156 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 32 |
| Metformin Hcl | Metformin Hcl | 118 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 110 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 38 |
| Farxiga | Dapagliflozin Propanediol | 102 | 32 |
| Carvedilol | Carvedilol | 101 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 98 | 36 |
| Trazodone Hcl | Trazodone Hcl | 97 | 35 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 94 | 36 |
| Montelukast Sodium | Montelukast Sodium | 86 | 29 |
| Ozempic | Semaglutide | 85 | 22 |
| Buspirone Hcl | Buspirone Hcl | 81 | 34 |
| Potassium Chloride | Potassium Chloride | 81 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 26 |
| Furosemide | Furosemide | 69 | 30 |
| Simvastatin | Simvastatin | 65 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 64 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 16 |
| Naproxen | Naproxen | 49 | 21 |
| Spironolactone | Spironolactone | 49 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 14 |
| Jardiance | Empagliflozin | 46 | 17 |
| Pregabalin | Pregabalin | 46 | suppressed |
| Methocarbamol | Methocarbamol | 45 | 19 |
| Methylprednisolone | Methylprednisolone | 45 | 36 |
| Alendronate Sodium | Alendronate Sodium | 44 | 14 |
| Meloxicam | Meloxicam | 40 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 39 | suppressed |
| Famotidine | Famotidine | 39 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 17 |
| Sertraline Hcl | Sertraline Hcl | 34 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 20 |
| Allopurinol | Allopurinol | 30 | 11 |
| Eliquis | Apixaban | 30 | suppressed |
| Fluconazole | Fluconazole | 30 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | 13 |
| Mirtazapine | Mirtazapine | 30 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | 13 |
| Azithromycin | Azithromycin | 28 | 26 |
| Glipizide | Glipizide | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | 14 |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | 12 |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 12 |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Nystatin | Nystatin | 16 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Euthyrox | Levothyroxine Sodium | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $281.76 · 15 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CAPLYTA, FARXIGA, JARDIANCE, Kerendia, NURTEC ODT, Ozempic, Rybelsus, VRAYLAR, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error